Funding for this research was provided by:
GlaxoSmithKline (ID 209140)
Received: 22 December 2020
Accepted: 13 May 2021
First Online: 7 June 2021
: All four studies were conducted in accordance with the ethical principles of the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice Guidelines, and applicable country-specific regulatory requirements.
: Not applicable.
: PGG reports grants and personal fees from GSK; grants and personal fees from AstraZeneca; and personal fees from Novartis and Sanofi. CMP, ESB, SAM, SGS and SWY are employees of GSK and hold stocks/shares. MF is a former employee of GSK and holds stocks/shares, and is currently employed by Vertex Pharmaceuticals. GLC has acted as a consultant, for AstraZeneca, Genentech, Boehringer Ingelheim, and Teva; attended a speakers' bureau with AstraZeneca, Genentech, and Circassia; and received research grants from AstraZeneca and institutional grants from AstraZeneca, Genentech, Boehringer Ingelheim, and GSK. EHB reports grants from AstraZeneca, GSK, and Novartis; and personal fees from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Sanofi/Regeneron, Teva, Sterna, and Vectura.